Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Comparing the efficacy and safety of the ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) with traditional “3+7” intensive induction regimen or AB-14 regimen (Venetoclax Combined with Azacitidine) in newly diagnosed AML: Study protocol for a prospective, multicenter, randomized, open-label clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

HYHong-Hong YanXHXin HuangPWPing Wu

Discussion

Loading...

Member takes

Overview

Prospective trial compares ABC-14 and 3+7 regimens in newly diagnosed AML, suggesting potential improvements in safety and outcomes.

Key Points

  • This trial aims to compare the efficacy and safety of the ABC-14 regimen versus traditional regimens in newly diagnosed acute myeloid leukemia.
  • Patients will be stratified into unfit-AML and fit-AML based on suitability for intensive chemotherapy.
  • Unfit-AML patients will receive either ABC-14 or AB-14 regimen; fit-AML patients will receive ABC-14 or 3+7 regimen.
  • Primary endpoint is composite complete response rate; secondary endpoints include measurable residual disease rate and overall survival.
  • Comparison seeks to demonstrate that ABC-14 is safer and similarly effective as the traditional 3+7 regimen.
  • Exploratory endpoints include quality of life and blood product transfusion rates among others.

Cite This Study

Yan et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1e5https://doi.org/10.1182/blood-2025-8252
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional “3 + 7” intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial2025
  2. 2The ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) as a bridge to allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia: A single-center experience2025
  3. 3A prospective study of all-trans retinoic acid plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia.2024 · 2 citations
  4. 4A prospective observational study to compare the efficacy, time toxicity, and cost of conventional 3+7 regimen versus azacitidine + venetoclax (AZA + VEN) as induction therapy in patients with acute myeloid leukemia (AML).2026 · 1 citations
  5. 5Venetoclax-azacitidine in combination with chidamide and CAG versus daunorubicin and cytarabine in newly diagnosed AML2025